Compare Apollo Global Management Ord Shs (APO) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apollo Global Management Ord Shs vs IDEXX Laboratories, Inc. — how do they compare? Apollo Global Management Ord Shs trades at $120 (market cap $69.38B), while IDEXX Laboratories, Inc. trades at $565 (market cap $44.46B). The key difference: Apollo Global Management Ord Shs is the larger of the two by market cap, and Apollo Global Management Ord Shs pays a 1.87% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| APO | IDXX | |
|---|---|---|
Market Cap | $69.38B | $44.46B |
Sector | Financials | Health |
52-Week High | $156.05 | $766.68 |
52-Week Low | $100.30 | $514.61 |
Enterprise Value | -$168.19B | $45.36B |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $120.34, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $1.94, beating estimates, and maintains strong analyst support with 23 buy ratings. Recent news highlights private credit growth opportunities alongside liquidity concerns in Apollo's funds.
APO's outlook is supported by earnings beats and a $149.86 consensus price target, but risks include private credit liquidity pressures and a high P/E ratio of 75.69. Investor sentiment is mixed due to ongoing fund withdrawal caps and legal investigations, though long-term growth in alternative assets remains a positive catalyst.
IDXX trades at $563.57, up 0.89% today, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.47 surpassing estimates. Revenue grew to $4.3B in 2025, with a robust net income margin of 24.63%. Analyst consensus is bullish with a $645 price target. Recent news highlights innovation in veterinary diagnostics and AI integration.
The outlook remains positive driven by earnings growth and market leadership, though high valuation multiples pose a risk. Key catalysts include upcoming Q2 2026 results and continued demand in pet healthcare. Risks involve competitive pressures and macroeconomic sensitivity. The stock offers growth potential but requires monitoring of valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
